Press release from Companies
Published: 2012-10-30 15:39:30
WntResearch AB (WNT.ST) announces positive results from the FOXY-5 four weeks pre-clinical toxicology studies. The conclusion is that FOXY-5 was well tolerated with no unexpected toxicity observed. These data will be part of the Clinical Trial Application to EMA (the European health authorities), which the Company expects to file in order to initiate Phase 1 clinical trial at the end of 2012/beginning of 2013.
CEO Nils Brünner comments: "These very positive results mean that we can keep our time plan and expect to initiate the clinical phase 1 study end of 2012/beginning of 2013." For further information please contact: Nils Brünner, CEO E-mail: nbr@wntresearch.com Telephone: +45 2614 4708
